<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <title>Loratadine - Medications - Offline Clinical Reference</title>
  <link rel="stylesheet" href="../sickbay-shared.css">
</head>
<body>
  <div class="topbar">
    <div class="topbar-inner">
      <span class="pill"><strong>Loratadine</strong></span>
      <span class="spacer"></span>
      <div class="nav-btns">
        <a class="btn small" href="../../index.html">Home</a>
        <a class="btn small" href="../../index.html#/sickbay-meds">Back to Medications</a>
      </div>
    </div>
  </div>

  <main class="wrap">
    <section class="section">
      <div class="kicker">Respiratory / Allergy</div>
      <h1>Loratadine</h1>

      <div class="content">
        <h3>Stocked on board</h3>
        <ul>
          <li>Loratadine 10mg Tablets</li>
        </ul>

        <div class="rule"></div>

        <h3>Adult dosing</h3>
        <ul>
          <li><strong>Allergic rhinitis (seasonal/perennial)</strong>
            <ul>
              <li>10 mg PO once daily</li>
            </ul>
          </li>
          <li><strong>Urticaria (hives) / pruritus from allergic triggers</strong>
            <ul>
              <li>10 mg PO once daily</li>
            </ul>
          </li>
          <li><strong>Dose adjustments</strong>
            <ul>
              <li>Hepatic impairment or renal impairment (CrCl &lt;30 mL/min): 10 mg every other day (or follow product monograph/local guidance)</li>
            </ul>
          </li>
        </ul>

        <div class="rule"></div>

        <h3>Indications</h3>
        <ul>
          <li>Symptomatic relief of allergic rhinitis (sneezing, rhinorrhea, itchy/watery eyes, nasal/palatal pruritus)</li>
          <li>Symptomatic relief of chronic idiopathic urticaria and other allergic skin conditions</li>
        </ul>

        <div class="rule"></div>

        <h3>Contraindications / cautions</h3>
        <ul>
          <li>Hypersensitivity to loratadine or any component</li>
          <li>Generally considered non-sedating, but drowsiness can occur in some individuals; caution with watchkeeping, machinery, and alcohol/sedatives</li>
          <li>Hepatic or severe renal impairment: dose adjustment required</li>
          <li>Pregnancy/breastfeeding: use only if clearly needed; consult product monograph/medical direction</li>
        </ul>

        <div class="rule"></div>

        <h3>Adverse effects</h3>
        <ul>
          <li>Headache (most common)</li>
          <li>Fatigue, drowsiness (less common than first-generation antihistamines; similar to cetirizine or less sedating)</li>
          <li>Dry mouth</li>
          <li>Nausea, GI upset (uncommon)</li>
          <li>Rare: tachycardia, palpitations, dizziness</li>
        </ul>

        <div class="rule"></div>

        <h3>Preparation &amp; administration</h3>
        <ul>
          <li>PO tablet; may take with or without food</li>
          <li>Non-sedating for most patients; can be taken in morning or evening based on preference and symptom timing</li>
          <li>Avoid combining with other sedating medications/alcohol when possible</li>
          <li>Onset of action typically within 1â€“3 hours; duration ~24 hours</li>
        </ul>

        <div class="rule"></div>

        <h3>Monitoring</h3>
        <ul>
          <li>Symptom control (rhinitis/urticaria)</li>
          <li>Sedation/functional impairment (though less likely than with first-generation antihistamines or cetirizine)</li>
          <li>Reassess need for ongoing therapy and consider step-down or discontinuation if symptoms resolve</li>
        </ul>

        <div class="rule"></div>

        <h3>At-sea considerations</h3>
        <ul>
          <li>Preferred antihistamine if minimal sedation is critical (e.g., watchkeepers, pilots, machinery operators)</li>
          <li>Operational safety: generally well-tolerated, but warn about potential drowsiness in sensitive individuals; consider trial dose at a non-critical time</li>
          <li>If symptoms are primarily nasal congestion, ensure non-sedating options and local pathways are also considered (e.g., nasal steroid use if stocked and appropriate)</li>
          <li>Document response and any sedation to guide future selection (loratadine vs cetirizine, etc.)</li>
        </ul>

        <div class="rule"></div>

        <h3>Online-only references</h3>
        <ul>
          <li>Health Canada product monograph (loratadine / Claritin): <a href="https://pdf.hres.ca/dpd_pm/00068011.PDF" target="_blank" rel="noopener">https://pdf.hres.ca/dpd_pm/00068011.PDF</a></li>
          <li>Health Canada product monograph (APO-loratadine): <a href="https://pdf.hres.ca/dpd_pm/00063861.PDF" target="_blank" rel="noopener">https://pdf.hres.ca/dpd_pm/00063861.PDF</a></li>
        </ul>
      </div>

      <p class="foot">
        Verify dosing and indications against current clinical guidelines.
      </p>
    </section>
  </main>
</body>
</html>
